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ABSTRACT 
Objective: The pharmacokinetics and pharmacodynamics of drugs in critically ill patients are difficult to predict due to complex pathophysiological 
changes. Vancomycin is an antibiotic commonly used to treat serious gram positive bacterial infections in critically ill patients and the treatment 
goal is to rapidly achieve and maintain therapeutic concentrations. We assessed the pharmacokinetics of vancomycin in critically ill patients to help 
guide dosing. 
Methods: A total of 138 patients with 299 vancomycin serum concentrations were included in this analysis. Vancomycin serum concentrations 
were measured using a fluorescence polarization immunoassay. Population pharmacokinetic parameters were estimated using nonlinear mixed 
effects regression. Age, creatinine clearance (CrCL) and body weight were tested as potential covariates in the pharmacokinetic model.  
Results: Vancomycin concentration-time profiles were best described by a two-compartment pharmacokinetic model with an additive error model 
for between subject variability. Creatinine clearance significantly influenced vancomycin clearance (CL). Mean population pharmacokinetic 
parameters (% between subject variability) were: CL 3.39 l/h (13%), central compartment volume of distribution (V1) 24.92 l (26%); and 
peripheral compartment volume of distribution (V2) 24.6 (37%).  
Conclusion: Higher clearance and a smaller volume of distribution of vancomycin was observed in critically-ill patients compared to those reported 
in non-critically ill patients with a similar distribution of renal function and body weight. Close monitoring of vancomycin serum concentrations is 
warranted in critically ill patients with dose interval adjustments based on the patient’s creatinine clearance. 
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INTRODUCTION 
Vancomycin is a tricyclic glycopeptide antibiotic with a different 
mechanism of action to penicillins and cephalosporins, its bacterial 
killing property is time-dependent and it has limited post-antibiotic 
effects [1-3]. Vancomycin is a bactericidal with a narrow-spectrum but is 
active against most gram-positive organisms [2, 4]. The goal of 
vancomycin dosing is to rapidly achieve and maintain therapeutic 
concentrations within the therapeutic range. The ratio of the area under 
the concentration-time curve at 24 hours to the minimum inhibitory 
concentrations (AUC24
At present, the breakpoint for Methicillin-resistant Staphylococcus 
aureus (MRSA) has been reduced from 4 to 2 mg/l [9]. Lower rates of 
treatment success due to higher MIC values support the need to revise 
this therapeutic range. An AUC
/MIC) is the recommended parameter to evaluate 
the effectiveness of vancomycin treatment [5-8]. 
24
After administration, vancomycin is extensively distributed 
throughout the body [11] and is primarily eliminated through 
glomerular filtration. Differences in vancomycin clearance (CL) have 
been observed in patients with different degrees of renal function. 
Morbidly obese adults have been reported to have significantly 
higher vancomycin clearance compared to non-obese adults (187.5 
ml/min vs 80.0 ml/min) as well as differences in volume of 
distribution [12]. 
/MIC ratio of ≥ 400 has been 
proposed as the vancomycin therapeutic target for a pathogen with an 
MIC of 1.0 mg/l [6]. In 2009, the American Thoracic Society proposed a 
new vancomycin target trough range between 15-20 mg/l in adult 
patients with complicated infection caused by Staphylococcus aureus 
including hospital-acquired pneumonia (HAP) [10]. 
Vancomycin clearance has been shown to decline in the elderly but 
this may be the consequence of a reduction in renal blood flow, 
glomerular filtration rate (GFR) and creatinine clearance [13-14]. 
Vancomycin apparent volume of distribution was higher in the elderly 
compared to a younger age group (0.93 l/kg vs 0.64 l/kg) [13]. 
Therefore, factors which impact renal function and body composition 
may significantly influence vancomycin pharmacokinetics.  
Critically ill patients are those with any severe conditions which may 
cause deterioration, impairment or deficiency of at least one internal 
organ or physiology requiring invasive devices and progressive 
treatment with close monitoring [15]. Critically ill patients in ICU are 
typically at high risk of bacterial infection which can more than 
double mortality rates [16]. 
The prescription of antibiotics in critically ill patients is complicated 
due to pathophysiological changes in the patient’s organs. 
Understanding the pharmacokinetic and pharmacodynamic (PK/PD) 
properties of antibiotics in relation to bacterial susceptibility allows 
the appropriate selection of the initial and maintenance antibiotic 
dose [17]. 
Mahoney et al. (2006) reported that 61.4% of ICU patients with 
bacteremia and pneumonia who received vancomycin dosing based 
on a nomogram did not achieve the optimal trough concentration 
of>10 mg/l [18]. A study of 14 critically ill patients demonstrated 
that the penetration of vancomycin into lung tissue is poor [19]. 
Other studies have shown that using 1.0 gram of vancomycin every 
12 hours did not achieve the recommended vancomycin 
concentrations [11, 20].  
Data on the pharmacokinetics of vancomycin in critically ill patients 
are limited and there are no available guidelines for 
individualization vancomycin dosing. The vancomycin dose for these 
patients is based on the clinician’s own experience. Often these 
patients have several pathophysiological conditions which are likely 
to alter key pharmacokinetics parameters [21-22] making it difficult 
to ensure target therapeutic drug concentrations are achieved [22]. 
 Our objective was to determine the pharmacokinetics of 
vancomycin in critically ill patients to help guide antibiotic dosing to 
rapidly achieve therapeutic target concentrations. 
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MATERIALS AND METHODS 
Study population 
A prospective intensive pharmacokinetic study was conducted in 
critically ill patients who received vancomycin every 24 hours for 
gram positive bacterial infections in the intensive care unit and sub-
intensive care unit at Maharaj Nakorn Chiang Mai Hospital, Chiang 
Mai, Thailand. The study protocol was approved by the Institution 
Review Board at the Faculty of Medicine, Chiang Mai University. 
Informed consent was obtained from all patients.  Vancomycin drug 
concentration data were also collected retrospectively from 134 
critically ill patients in the intensive care unit at Bumrungrad 
International Hospital, Bangkok, who had vancomycin serum 
concentrations monitored between February, 2003 and July, 2014. 
This retrospective study was approved by the Institution Review 
Board at Faculty of Pharmacy, Chiang Mai University.  
Blood sample collection 
For the intensive PK study serial blood samples were collected at the 
time of the third vancomycin infusion. Three milliliters (ml) of blood 
were collected before vancomycin infusion, at the end of the 1-hour 
infusion (1.0) and then serially at 1.5, 2.0, 2.5, 3.0, 6.0, 12.0 and 24 
hours post-infusion.  
Retrospective data were extracted from patients’ records. Sixty eight 
patients (50.7%) received 1.0 gram of vancomycin infused 
intravenously over 2 hours every 12 hours. The other 66 patients 
(49.3%) received an average vancomycin dose of 15.9±4.5 
mg/kg/dose every 12, 24 or 48 hours with an infusion rate of 500 
mg/h based upon their renal function. At steady state, peak 
concentrations were obtained 2 hours after the end of infusion. 
Vancomycin trough concentrations were measured an hour before 
the next dose or at least two half-lives after the first blood sample.  
Measurement of vancomycin serum concentrations 
Blood samples were allowed to clot for 15 minutes then centrifuged 
at 3,000 RPM for 10 minutes (Spinchron® DLX Centrifuge, Beckman 
coulter) and the serum stored at -25°C until analysis. Vancomycin 
serum concentrations were measured using the fluorescence 
polarization immunoassay (FPIA) by Abbott AxSYM® Vancomycin II 
(Abbott Laboratories, TX, USA). Controls of 7.0, 35.0 and 75.0 µg/ml 
of vancomycin were used. The average accuracy was 102.5±2.5% 
and the precision was less than 7% of the coefficient of variation 
(%CV). The minimum detectable concentration was 2 µg/ml.  
Pharmacokinetic analysis 
The population analysis was executed using Phoenix® NLME 1.2 
software (CertaraTM
A total of 138 ICU patients with 299 serum vancomycin specimens at 
steady state (4 patients with 31 observation points from intensive 
blood samplings and 134 patients with 268 concentrations from 
sparse blood samplings) were included in this analysis. The patient 
characteristics data are shown in table 1. 
The serum vancomycin concentrations versus time profiles are 
shown in fig. 1. 
Vancomycin serum concentrations were best described by a two-
compartmental model with first-order elimination. The residual un 
explained variability (RUV) was described using an additive error model. 
, St. Louis, MO, USA). One-, two-and three-
compartmental models with first-order elimination were fitted to 
the data. First-Order Conditional Estimation with Extended Least 
Squares (FOCE-ELS) was used for all analyses.  
Pharmacokinetic models were assessed using both statistical and 
graphical methods. The objective function value, OFV (i.e. -2x Log-
likelihood, -2LL) was used as a cut-off criteria for model 
improvement and covariate effect(s) on pharmacokinetic 
parameter(s). Additive, multiplicative, power and mixed model were 
investigated to describe the residual variability model.  
Individual patient characteristics that could potentially influence 
vancomycin pharmacokinetic parameters were evaluated for 
inclusion in the model. Covariates tested was total body weight, age 
and estimated renal functions using a stepwise forward inclusion 
and backward elimination model building procedure. Models were 
compared by observing a decrease of -2LL by 6.63 (p=0.01) for 
forward inclusion and 10.83 (p=0.001) for backward deletion. A 
decrease in between subject variability (BSV) was also another 




Fig. 1: It shows observed vancomycin serum concentrations 
versus time profiles in critically-ill patients [4 patients with 
intensive (dotted line) and 134 patients with TDM samples (299 
open circles)] 
 
Among covariates tested for their influence on vancomycin 
pharmacokinetic parameters, only creatinine clearance was found to 
significantly influence vancomycin clearance. The degree of between 
subject variability (BSV %) of CL was 13.0% when creatinine 
clearance was included in the model. The population 
pharmacokinetic parameters from the final model are shown in table 
3 and goodness of-fit plots are shown in fig. 2. 
The final model for vancomycin clearance was achieved using the 
following equation:  
tv Cl (l/hr) = THETA(3) x CrCL
 
(THETA(4)) 
Where tv stands for the typical value and THETA is the final 
parameter estimate. 
Fig. 2: It shows Observed (DV) versus predicted (PRED) 
vancomycin concentrations 
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Table 1: It shows demographic characteristics 
Characteristics Value (mean±SD) [median, range] 
Number of subjects 138 
Gender (M/F) 72/66 
Age (y) 65.7±17.6 [69,18-97] 
Body weight (kg) 62.1±13.7 [62.0, 31.7-105.0] 
CrCL* (ml/min) 54.5±29.1 [51.4, 10.03-105.00] 
Body Mass Index (kg/m2) 23.5±4.4 [23.9, 13.19-34.52] 
SAP II score (point) 46.7±5.6 [45.5, 39-52] 
Total daily dose (mg/kg/dose) 
Type of infections 
15.9±4.5[18.2, 6.45-30.0] 
 
-Bacteremia [n (%)] 55 (39.8) 
-Pneumonia [n (%)] 53 (38.4) 
-Skin & soft tissue [n (%)] 15 (10.9) 
-Meningitis [n (%)] 11 (8.0) 
-Others [n (%)] 4 (2.9) 
Mechanical ventilation [n (%)] 113 (81.9) 
Vasoactive drugs [n (%)] 88 (63.8) 
* Estimating by Cockroft and Gault equation 
From the retrospective therapeutic drug monitoring (TDM) data, only 18.6% (25 of 134 patients) of the patients achieved the recommended 
concentrations (15-20 mg/l). After separating these patients based on renal function: Group I: CrCL<30 ml/min, Group II: CrCL 30-60 ml/min and 
Group III: CrCL>60 ml/min. There was no difference in the percentage of patients who achieved vancomycin trough concentrations (table 2).  
 
Table 2: It shows vancomycin trough serum concentrations achievement based on renal function 





at 15-20 mg/l (n, %) 














Group III: CrCL>60 ml/min 






CrCL: Creatinine clearance using Cockcroft and Gault equation 
 
Table 3: It shows vancomycin population pharmacokinetic parameters from the final model 
Parameters Estimate (%RSE) BSV (%RSE) 
Cl = THETA(3) x CrCL  (THETA(4)) 13.97 (13.03) 
 THETA(3) 0.27 (23.97)  
 THETA(4) 0.63 (9.65)  
V (l) 24.92 (12.77) 45.97 (25.57) 
V2 (l) 24.59 (11.91) 36.54 (36.55) 
CL2 (l/h) 10.54(13.38) 109.28 (32.59) 
Additive error 1.60µg/l (12.59)  
Cl: systemic clearance; V: central compartment volume of distribution; V2: peripheral compartment volume of distribution; CL2: distributive 
clearance; RSE: relative standard error of the estimates; BSV: Between subject variability (%CV). 
 
 
Fig. 3: It shows conditional weighted residuals (CWRES) versus 
predicted concentrations (PRED) plots for the final 
pharmacokinetic model 
DISCUSSION 
The majority of pharmacokinetic studies of vancomycin were 
performed in healthy volunteers using multi-compartment 
pharmacokinetics models. Creatinine clearance, body size and age 
were identified as significant covariates affecting vancomycin 
pharmacokinetic parameters [23, 26].  
In our study, vancomycin serum concentration time profiles 
were best described by a two-compartmental model with first-
order elimination. A strong correlation between creatinine 
clearance and vancomycin clearance was observed and including 
creatinine clearance in the model reduced the between subject 
variability of CL. 
Previous studies also reported a relationship between creatinine 
clearance and vancomycin clearance [23-25]. Llopis-Salvia et al.’s 
also found that body weight influenced vancomycin clearance [26].  
It should be noted that the ages of the subjects in these studies were 
comparable. 
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Significant variability and changes in both clearance and volume of 
distribution of vancomycin as well as the plasma vancomycin 
concentrations in ICU and non-ICU patients during the course of 
therapy is well documented [21-22, 27].  
The mean estimate of the vancomycin clearance in our study was 3.39 
l/h. A summary of the pharmacokinetic data from previous studies 
investigating vancomycin are shown in table 4. A two-compartment 
pharmacokinetic model was implemented in each of these studies. 
  
Table 4: It shows population pharmacokinetic models of vancomycin 
Study  
(N, Type of patients) 
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CL: Vancomycin clearance (l/h); V1:central compartment volume of distribution of vancomycin (l); V2:peripheral compartment volume of 
distribution of vancomycin (l); Vss: Estimate of the vancomycin volume of distribution at steady state=MRTINF*Clss; CL2:distributive clearance 
(l/h); K12:rate constant for the flow between the central and peripheral compartments (h-1); K21:rate constant for the flow between the peripheral 
and central compartment (h-1); a: group with Creatinine clearance<85 ml/min using Cockcroft and Gault equation; b: group with Creatinine 
clearance>85 ml/min using Cockcroft and Gault equation; c: 
 
group with Creatinine clearance ≤ 85 ml/min using Cockcroft and Gault equation; BSV: 
Between subject variability 
The clearance of vancomycin in our study is comparable to those in 
infected non-ICU patients, despite the creatinine clearance of our 
patients being lower than those in non-ICU patients [24-25]. Other 
patient factors such as the administration of intravenous fluid 
during the resuscitation and the administration of hemodynamic 
active drugs (e. g. dopamine, dobutamine and diuretics) may explain 
these discrepancies and partly dilute the effect of creatinine 
clearance on the elimination of vancomycin in these critically ill 
patients [5, 27]. 
No significant covariates were found to influence the volume of 
distribution, similar to the results from Yasuhara et al.’s study [25]. 
However, other studies by Yamamoto et al., Thomson et al. and Llopis-
Savia et al. observed that body weight was a significant covariate on 
vancomycin volume of distribution [24, 26, 29]. Sanchez et al. and 
Purwonugroho et al. found that age was an influential covariate on 
vancomycin volume of distribution [23, 28]. Moreover, Yamamoto et 
al. also found that the patient’s status (healthy and infected) as a 
significant covariate influencing the volume of distribution of 
vancomycin. The steady state volumes of distribution were larger in 
infected patients than healthy volunteers. In addition, central 
compartment volumes of distribution were highest in patients with 
pneumonia compared to patients with other infections [24]. 
It has been proposed that increases in capillary or vascular 
permeability from infections, stress, or sepsis results in fluid leaking 
from the intravascular compartment or fluid extravasation to the 
interstitial space or third spacing may result in an increase in 
vancomycin volume of distribution but, we did not observed 
increase in the volume of distribution of vancomycin compared with 
previously report values.  
However, it should be noted that the timing of the available 
vancomycin concentration data in our retrospective study was 
primarily during the elimination phase and a limitation of our study 
was that only a few patients had full pharmacokinetic profiles 
available.  
When comparing studies in ICU patients, the vancomycin volume of 
distribution at steady state (Vdss) observed by Llopis-Salvia and 
collogues’ and Polard et al. had the highest values (1.73 l/kg and 
0.88 l/kg), while in our study it was 0.80 l/kg [27]. 
It was also observed that the vancomycin volume of distribution at 
steady state was larger in non-ICU patients compared to ICU-
patients. The study by Purwonugroho et al. in infected (non-ICU)-
Thai patients also observed a larger volume of distribution for 
vancomycin at steady state compared to our study (1.54 l/kg 
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vs0.80l/kg). However, the higher volume of distribution of 
vancomycin may correspond to older age or as a surrogate of their 
underlying disease [28]. 
Current guidelines by the American Thoracic Society (ATS) 
recommend an initial vancomycin dose of 15 mg/kg every 12 hours 
in adult patients with normal renal function. Vancomycin trough 
serum concentration at steady state should be maintained between 
15-20 mg/l for pneumonia [30]. In this study, approximately 80% of 
our ICU patients did not attain the recommended vancomycin trough 
concentration. Similarly, del Mar Fernandez found that one-third of 
patients did not achieve the recommended AUC24
To determine the maintenance dose and dosing interval of 
vancomycin in critically ill patients, increasing frequency of 
vancomycin administration may be necessary comparing to non-ICU 
patients with the similar degree of kidney functions. A larger loading 
dose of vancomycin is less likely to be required for these patients as 
compare to other populations. However, since the vancomycin 
volume of distribution displays high patient variability, close 
monitoring of vancomycin serum concentrations may be warranted. 
/MIC breakpoint 
for S. aureus infections using 1 gram of vancomycin. A larger Vd 
(1.73 l/kg) than the Vd from our study (0.80 l/kg) was found, likely 
due to sepsis resulting in fluids leaking in to the third space [8]. 
CONCLUSION 
Vancomycin pharmacokinetics profiles in critically ill patients were 
best described by a two-compartment model. Only creatinine 
clearance was found to significantly influence the systemic clearance 
of vancomycin. However, vancomycin clearance was higher, and the 
volume of distribution smaller compared to non-ICU patients with 
the same degree of renal function and body size. Thus, adjusting the 
vancomycin dosing interval based on creatinine clearance in 
critically-ill patients should be practiced with caution. Close 
monitoring of serum concentrations is recommended due to 
multiple factors affecting the pharmacokinetics of vancomycin in 
critically-ill patients. 
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